🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are on the rise globally, with figures suggesting over 82 million instances annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This drug, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This authorization marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

As per findings published in a prominent scientific publication, the new drug eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial involved nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to license and sell the drug in many developing nations.

Medical professionals treating patients have voiced positive views. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is deemed essential to alleviate the strain of the illness for patients and to prevent the spread of extremely resistant gonorrhoea around the world.